Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...
More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.
Findings were announced from a phase 3 trial evaluating guselkumab subcutaneous (SC) induction therapy in patients with moderately to severely active ulcerative colitis (UC). Study participants ...
Hosted on MSN18d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis PatientsSPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with ...
Recommendation based on the findings from the Phase 3 QUASAR programme in ulcerative colitis 1. Beerse, Belgium (28 February 2025) - Johnson & Johnson today announced that the Com ...
Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...
Spring House, Pennsylvania Monday, February 24, 2025, 09:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback